Analysts Are Bullish on Top Healthcare Stocks: uniQure (QURE), Prometheus Biosciences (RXDX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on uniQure (QURE – Research Report), Prometheus Biosciences (RXDX – Research Report) and MDxHealth S.A. Sponsored ADR (MDXH – Research Report) with bullish sentiments.

uniQure (QURE)

BTIG analyst Yun Zhong reiterated a Buy rating on uniQure on December 1 and set a price target of $38.00. The company’s shares closed last Friday at $26.03.

According to TipRanks.com, Zhong has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -18.6% and a 31.5% success rate. Zhong covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Applied Genetic Technologies, and Mereo Biopharma Group Plc.

Currently, the analyst consensus on uniQure is a Strong Buy with an average price target of $56.00, representing a 120.6% upside. In a report issued on November 17, RBC Capital also maintained a Buy rating on the stock with a $53.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Prometheus Biosciences (RXDX)

BTIG analyst Julian Harrison reiterated a Buy rating on Prometheus Biosciences on December 1 and set a price target of $74.00. The company’s shares closed last Friday at $40.00.

According to TipRanks.com, Harrison is ranked 0 out of 5 stars with an average return of -11.7% and a 36.4% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Aclaris Therapeutics, and Outlook Therapeutics.

Prometheus Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $64.00.

MDxHealth S.A. Sponsored ADR (MDXH)

In a report issued on November 30, Mark Massaro from BTIG reiterated a Buy rating on MDxHealth S.A. Sponsored ADR, with a price target of $12.00. The company’s shares closed last Friday at $6.94.

According to TipRanks.com, Massaro is ranked 0 out of 5 stars with an average return of -5.7% and a 38.4% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Adaptive Biotechnologies, Ginkgo Bioworks Holdings, and Castle Biosciences.

MDxHealth S.A. Sponsored ADR has an analyst consensus of Moderate Buy, with a price target consensus of $12.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on QURE:

• uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event
• uniQure reports on progress made in developing AMT-260
• uniQure to hold a virtual event
• QURE: The Most Expensive Treatment EVER Is Here
• uniQure announces FDA approval of first gene therapy for adults with hemophilia B